Wen-Jing Zhang

Mitochondrial metabolic-transcriptional axis drives adaptive drug tolerance across major lung cancer subtypes

Drug resistance remains the first and most significant barrier to long-term curative benefits in lung cancer patients. Traditional resistance mechanisms focused on oncogenic driver mutations are inadequate to explain reversible tumor phenotypic plasticity under therapeutic stress. Increasing evidence has placed mitocho...